Travere Therapeutics Stock Probability of Future Stock Price Finishing Over 6.96
| TVTX Stock | USD 17.32 0.59 3.29% |
Travere |
Travere Therapeutics Target Price Odds to finish over 6.96
The tendency of Travere Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 6.96 in 90 days |
| 17.32 | 90 days | 6.96 | close to 99 |
Based on a normal probability distribution, the odds of Travere Therapeutics to stay above $ 6.96 in 90 days from now is close to 99 (This Travere Therapeutics probability density function shows the probability of Travere Stock to fall within a particular range of prices over 90 days) . Probability of Travere Therapeutics price to stay between $ 6.96 and its current price of $17.32 at the end of the 90-day period is about 54.84 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.29 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Travere Therapeutics will likely underperform. Additionally Travere Therapeutics has an alpha of 0.4278, implying that it can generate a 0.43 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Travere Therapeutics Price Density |
| Price |
Predictive Modules for Travere Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Travere Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Travere Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Travere Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Travere Therapeutics is not an exception. The market had few large corrections towards the Travere Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Travere Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Travere Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.43 | |
β | Beta against Dow Jones | 1.29 | |
σ | Overall volatility | 1.88 | |
Ir | Information ratio | 0.12 |
Travere Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Travere Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Travere Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Travere Therapeutics had very high historical volatility over the last 90 days | |
| Travere Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 145.24 M. Net Loss for the year was (376.33 M) with loss before overhead, payroll, taxes, and interest of (31.35 M). | |
| Travere Therapeutics currently holds about 553.17 M in cash with (280.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65. | |
| Travere Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Travere Therapeutics SWOT analysis rare disease stock poised for growth |
Travere Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Travere Stock often depends not only on the future outlook of the current and potential Travere Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Travere Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 74.3 M | |
| Cash And Short Term Investments | 566.9 M |
Travere Therapeutics Technical Analysis
Travere Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Travere Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Travere Therapeutics. In general, you should focus on analyzing Travere Stock price patterns and their correlations with different microeconomic environments and drivers.
Travere Therapeutics Predictive Forecast Models
Travere Therapeutics' time-series forecasting models is one of many Travere Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Travere Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Travere Therapeutics
Checking the ongoing alerts about Travere Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Travere Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Travere Therapeutics had very high historical volatility over the last 90 days | |
| Travere Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 145.24 M. Net Loss for the year was (376.33 M) with loss before overhead, payroll, taxes, and interest of (31.35 M). | |
| Travere Therapeutics currently holds about 553.17 M in cash with (280.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65. | |
| Travere Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Travere Therapeutics SWOT analysis rare disease stock poised for growth |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.